{
    "clinical_study": {
        "@rank": "132880", 
        "arm_group": {
            "arm_group_label": "low dose 5'-azacitidine", 
            "arm_group_type": "Experimental", 
            "description": "This is a single arm phase II trial to assess the efficacy and confirm the safety of maintenance therapy with 5'-azacitadine compared to historical control after TCD allogeneic hematopoietic stem cell transplant for patients with MDS and AML who are at high risk of relapse."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to learn if 5'-Azacitidine will help to lower the risk of the\n      disease coming back after a stem cell transplant in patients with MDS and AML. This study\n      will also be looking at the side effects of this medicine.\n\n      5'-Azacitidine is an FDA approved drug for treatment of MDS and AML, as well as patients\n      whose disease came back after transplant, where it helped going into remission. It is\n      unclear if 5'-Azacitidine can prevent the disease from coming back after transplant. This\n      study will help show if getting 5'-Azacitidine soon after transplant can lower the risk of\n      your disease coming back."
        }, 
        "brief_title": "Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse", 
        "condition": [
            "Myelodysplastic Syndromes (MDS)", 
            "Acute Myelogenous Leukemia (AML)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid, Acute", 
                "Leukemia, Myeloid", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients who have undergone T cell depleted allogeneic hematopoietic stem cell\n        transplantation at MSKCC for:\n\n          -  De novo myelodysplastic syndromes (MDS): IPSS-1 with poor risk cytogenetics or higher\n             IPSS.\n\n          -  Acute myelogenous leukemia (AML) in first remission that required more than 1 cycle\n             of treatment to achieve remission or with the following cytogenetic abnormalities:\n             FLT3 mutation, deletion/monosomy of chromosome 5 or 7, MLL gene rearrangement, or\n             more than or equal to 3 cytogenetics abnormalities. Also patients in second or\n             greater remission.\n\n          -  Patients with Secondary MDS/AML.\n\n          -  Patients will be considered eligible for the study if after transplant they achieved\n             hematologic (<5% blasts) and cytogenetic remission.\n\n          -  Patients will be eligible to enter the study between 60-120 days post transplant.\n\n          -  Age: pediatrics and adults patients - 1 year old-75 years old.\n\n          -  Karnofsky performance status >=60% for patients >16yo and Lansky performance status\n             >=60% for patients \u226416yo\n\n          -  Stable blood counts (ANC>1000/uL, Hb>8gr/dL, Plt>50,000/ uL) not supported by\n             transfusions.\n\n          -  Renal: Serum creatinine <1.5 ULN\n\n          -  Hepatic: <3xULN ALT and <1.5 total serum bilirubin, unless there is congenital benign\n             hyperbilirubinemia.\n\n          -  Cardiac: Adequate cardiac function measured by LVEF>50%. If asymptomatic,\n             pretransplant echocardiogram is adequate. If symptomatic, echocardiogram needs to be\n             repeated.\n\n          -  Each patient must be willing to participate as a research subject and must sign an\n             informed consent form.\n\n        Exclusion Criteria:\n\n        Patients will be excluded from the trial if at time of enrollment:\n\n          -  Active uncontrolled bacterial, fungal or viral infection.\n\n          -  Evidence of uncontrolled graft-versus-host disease.\n\n          -  Pulmonary: new onset hypoxia\n\n          -  Known or suspected hypersensitivity to 5'-azacitadine or mannitol.\n\n               -  Evidence of residual disease either by increased blasts count (>5%) or\n                  persistence of previous known cytogenetics abnormalities.\n\n          -  Peripheral blood neutrophil chimerism: less than 95% donor."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "1 Year"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01995578", 
            "org_study_id": "13-192"
        }, 
        "intervention": {
            "arm_group_label": "low dose 5'-azacitidine", 
            "description": "5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.", 
            "intervention_name": "low dose 5'-azacitidine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Azacitidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "5'-Azacitidine", 
            "Stem cell transplant", 
            "13-192"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "link": {
            "description": "Memorial Sloan-Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": [
            {
                "contact": {
                    "last_name": "Roni Tamari, MD", 
                    "phone": "212-639-5987"
                }, 
                "contact_backup": {
                    "last_name": ", MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Basking Ridge", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07920"
                    }, 
                    "name": "Memorial Sloan Kettering at Basking Ridge"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Roni Tamari, MD", 
                    "phone": "212-639-5987"
                }, 
                "facility": {
                    "address": {
                        "city": "Commack", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11725"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center @ Suffolk"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Roni Tamari, MD", 
                    "phone": "212-639-5987"
                }, 
                "contact_backup": {
                    "last_name": "Hugo Castro-Malaspina, MD", 
                    "phone": "212-639-8197"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Roni Tamari, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Roni Tamari, MD", 
                    "phone": "212-639-5987"
                }, 
                "facility": {
                    "address": {
                        "city": "Rockville Centre", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Memorial Sloan-Kettering at Mercy Medical Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Roni Tamari, MD", 
                    "phone": "212-639-5987"
                }, 
                "facility": {
                    "address": {
                        "city": "Sleepy Hollow", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10591"
                    }, 
                    "name": "Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse", 
        "overall_contact": {
            "last_name": "Roni Tamari, MD", 
            "phone": "212-639-5987"
        }, 
        "overall_contact_backup": {
            "last_name": "Hugo Castro-Malaspina, MD", 
            "phone": "212-639-8197"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Roni Tamari, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Relapse of MDS or AML will be analyzed as to type and genetic origin of the leukemic cells. These will be defined by morphologic and/or cytogenetic criteria: an increasing number of blasts in the marrow over 5%, by presence of circulating blasts, or by presence of blasts in any extramedullary site as well as presence of previous cytogenetic abnormalities. Other studies assessing for MRD, FACS and FISH assays will be evaluated but would not be considered disease relapse if positive since they are experimental.", 
            "measure": "relapse rate", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01995578"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Kaplan-Meier methodology will be used to compare overall survival.", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The safety will be described by tabulating the number of transfusions, frequencies of bleeding and serious infections, and the use of G-CSF support.", 
                "measure": "safety", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}